MULTIPLE SCLEROSIS: NEW IMMUNOMODULATORY STRATEGIES AND BIOMARKERS
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6099Keywords:
Multiple Sclerosis, Progression Independent of Eelapse Activity, Fluid Biomarkers, Disease-Modifying Therapies, PharmacoeconomicsAbstract
Introduction and purpose: Multiple Sclerosis (MS) disability accumulation is driven primarily by compartmentalized, subclinical neuroinflammation and diffuse neurodegeneration, termed smouldering MS. While traditional disease-modifying therapies (DMTs) control peripheral relapses and focal MRI activity, halting this progression remains a major challenge. Consequently, the therapeutic landscape is shifting toward novel central nervous system-targeting strategies to prevent Progression Independent of Relapse Activity (PIRA). The clinical utility of these interventions relies on highly sensitive fluid biomarkers, including serum neurofilament light (sNfL), serum glial fibrillary acidic protein (sGFAP), and kappa free light chains (kFLC), to track neuroaxonal injury, astrogliosis, and intrathecal immunoglobulin synthesis. This review evaluates the latest clinical evidence for next-generation immunomodulatory therapies, specifically autologous hematopoietic stem cell transplantation, Bruton’s tyrosine kinase inhibitors, and anti-CD20 monoclonal antibodies, alongside the diagnostic and prognostic roles of these emerging biomarkers.
Materials and methods: The literature search was performed using PubMed, Scopus, Web of Science, and Google Scholar for articles published between 2020 and 2026. Keywords included: “multiple sclerosis”, “MS”, “serum neurofilament light”, “sNfL”, “serum glial fibrillary acidic protein”, “sGFAP”, “kappa free light chains”, “kFLC”, “autologous hematopoietic stem cell transplantation”, “aHSCT”, “brutons tyrosine kinase inhibitors”, “BTK inhibitors”, “tolebrutinib”, “anti-CD20”, “ofatumumab”, and “ublituximab”.
Conclusion: Preventing PIRA requires a paradigm shift toward early, high-efficacy DMT utilization guided by multimodal biomarker profiling (sNfL, GFAP, kFLC). Although socioeconomic barriers often restrict early access, long-term pharmacoeconomic data demonstrate that timely intervention mitigates the substantial financial and societal burden of accumulated disability. Ultimately, combining these proactive clinical strategies with emerging therapeutic mechanisms, such as NLRP3 inflammasome inhibition or selective remyelination, offers the most promising avenue to alter the disease course and optimize healthcare resource utilization.
References
Lorenzut, S., Negro, I. D., Pauletto, G., Verriello, L., Spadea, L., Salati, C., Musa, M., Gagliano, C., & Zeppieri, M (2025). Exploring the pathophysiology, diagnosis, and treatment options of multiple sclerosis. Journal of Integrative Neuroscience, 24(1). https://doi.org/10.31083/JIN25081
Boutitah-Benyaich, I., Eixarch, H., Villacieros-Álvarez, J., Hervera, A., Cobo-Calvo, Á., Montalban, X., & Espejo, C. (2025). Multiple sclerosis: Molecular pathogenesis and therapeutic intervention. Signal Transduction and Targeted Therapy, 10(1), 324. https://doi.org/10.1038/s41392-025-02415-4
Mathur, D., Mishra, B. K., Rout, S., Lopez-Iranzo, F. J., Lopez-Rodas, G., Vallamkondu, J., Kandimalla, R., & Casanova, B. (2021). Potential biomarkers associated with multiple sclerosis pathology. International Journal of Molecular Sciences, 22(19), 10323. https://doi.org/10.3390/ijms221910323
Maroto-García, J., Martínez-Escribano, A., Delgado-Gil, V., Mañez, M., Mugueta, C., Varo, N., García de la Torre, Á., & Ruiz-Galdón, M. (2023). Biochemical biomarkers for multiple sclerosis. Clinica Chimica Acta, 548, 117471. https://doi.org/10.1016/j.cca.2023.117471
Huss, A., Otto, M., Senel, M., Ludolph, A. C., Abdelhak, A., & Tumani, H. (2020). A score based on NfL and glial markers may differentiate between relapsing–remitting and progressive MS course. Frontiers in Neurology, 11. https://doi.org/10.3389/fneur.2020.00608
Hegen, H., Walde, J., Berek, K., Arrambide, G., Gnanapavan, S., Kaplan, B., Khalil, M., Saadeh, R., Teunissen, C., Tumani, H., Villar, L. M., Willrich, M. A. V., Zetterberg, H., & Deisenhammer, F. (2023). Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis Journal, 29(2), 169–181. https://doi.org/10.1177/13524585221134213
Yang, J., Hamade, M., Wu, Q., Wang, Q., Axtell, R., Giri, S., & Mao-Draayer, Y. (2022). Current and future biomarkers in multiple sclerosis. International Journal of Molecular Sciences, 23(11), 5877. https://doi.org/10.3390/ijms23115877
Levraut, M., Landes-Chateau, C., Mondot, L., Cohen, M., & Lebrun-Frenay, C. (2025). The kappa free light chains index and central vein sign: Two new biomarkers for multiple sclerosis diagnosis. Neurology and Therapy, 14(3), 711–731. https://doi.org/10.1007/s40120-025-00737-7
Klotz, L., Saraste, M., Airas, L., & Kuhlmann, T. (2025). Multiple sclerosis: 2024 update. Free Neuropathology, 6, 14–14. https://doi.org/10.17879/freeneuropathology-2025-6762
Zjukovskaja, C., Larsson, A., Cherif, H., Kultima, K., & Burman, J. (2022). Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis. Multiple Sclerosis and Related Disorders, 68, 104210. https://doi.org/10.1016/j.msard.2022.104210
Ruder, J., Dinner, G., Maceski, A., Berenjeno-Correa, E., Müller, A. M., Jelcic, I., Kuhle, J., & Martin, R. (2022). Dynamics of inflammatory and neurodegenerative biomarkers after autologous hematopoietic stem cell transplantation in multiple sclerosis. International Journal of Molecular Sciences, 23(18), 10946. https://doi.org/10.3390/ijms231810946
Mariottini, A., Marchi, L., Innocenti, C., Di Cristinzi, M., Pasca, M., Filippini, S., Barilaro, A., Mechi, C., Fani, A., Mazzanti, B., Biagioli, T., Materozzi, F., Saccardi, R., Massacesi, L., & Repice, A. M. (2022). Intermediate-intensity autologous hematopoietic stem cell transplantation reduces serum neurofilament light chains and brain atrophy in aggressive multiple sclerosis. Frontiers in Neurology, 13. https://doi.org/10.3389/fneur.2022.820256
Amin, M., & Hersh, C. M. (2023). Updates and advances in multiple sclerosis neurotherapeutics. Neurodegenerative Disease Management, 13(1), 47–70. https://doi.org/10.2217/nmt-2021-0058
Fox, R. J., Bar-Or, A., Traboulsee, A., Oreja-Guevara, C., Giovannoni, G., Vermersch, P., Syed, S., Li, Y., Vargas, W. S., Turner, T. J., Wallstroem, E., & Reich, D. S. (2025). Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis. New England Journal of Medicine, 392(19), 1883–1892. https://doi.org/10.1056/NEJMoa2415988
Reich, D. S., Arnold, D. L., Vermersch, P., Bar-Or, A., Fox, R. J., Matta, A., Turner, T., Wallström, E., Zhang, X., Mareš, M., Khabirov, F. A., Traboulsee, A., Grand’Maison, F., Jacques, F., Tyblova, M., Meluzinova, E., Ampapa, R., Valis, M., Hradilke, P., … Robertson, D. (2021). Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: A phase 2b, randomised, double-blind, placebo-controlled trial. The Lancet Neurology, 20(9), 729–738. https://doi.org/10.1016/S1474-4422(21)00237-4
de Sèze, J., Maillart, E., Gueguen, A., Laplaud, D. A., Michel, L., Thouvenot, E., Zephir, H., Zimmer, L., Biotti, D., & Liblau, R. (2023). Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Frontiers in Immunology, 14, 1004795. https://doi.org/10.3389/fimmu.2023.1004795
Delgado, S. R., Faissner, S., Linker, R. A., & Rammohan, K. (2024). Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. Journal of Neurology, 271(4), 1515–1535. https://doi.org/10.1007/s00415-023-12007-3
Hauser, S. L., Bar-Or, A., Cohen, J. A., Comi, G., Correale, J., Coyle, P. K., Cross, A. H., Seze, J. de, Leppert, D., Montalban, X., Selmaj, K., Wiendl, H., Kerloeguen, C., Willi, R., Li, B., Kakarieka, A., Tomic, D., Goodyear, A., Pingili, R., … Kappos, L. (2020). Ofatumumab versus teriflunomide in multiple sclerosis. New England Journal of Medicine, 383(6), 546–557. https://doi.org/10.1056/NEJMoa1917246
Steinman, L., Fox, E., Hartung, H.-P., Alvarez, E., Qian, P., Wray, S., Robertson, D., Huang, D., Selmaj, K., Wynn, D., Cutter, G., Mok, K., Hsu, Y., Xu, Y., Weiss, M. S., Bosco, J. A., Power, S. A., Lee, L., Miskin, H. P., & Cree, B. A. C. (2022). Ublituximab versus teriflunomide in relapsing multiple sclerosis. New England Journal of Medicine, 387(8), 704–714. https://doi.org/10.1056/NEJMoa2201904
Kazmi, M., Muraro, P. A., Mehra, V., Gabriel, I., De Matteis, E., Brittain, G., Mariottini, A., Nicholas, R., Silber, E., Lee, J., Pearce, R., Paul, R., Sormani, M. P., Signori, A., Potter, V., Olavarria, E., Malladi, R., Sharrack, B., & Snowden, J. A. (2025). Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT). British Journal of Haematology, 207(3), 977–991. https://doi.org/10.1111/bjh.20199
Häußler, V., Ufer, F., Pöttgen, J., Wolschke, C., Friese, M. A., Kröger, N., Heesen, C., & Stellmann, J. (2021). aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis. Annals of Clinical and Translational Neurology, 8(6), 1269–1278. https://doi.org/10.1002/acn3.51366
Kappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S., & Hauser, S. L. (2020). Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology, 77(9), 1–9. https://doi.org/10.1001/jamaneurol.2020.1568
Benkert, P., Maleska Maceski, A., Schaedelin, S., Oechtering, J., Zadic, A., Vilchez Gomez, J. F., Melie‐Garcia, L., Cagol, A., Galbusera, R., Subramaniam, S., Lorscheider, J., Galli, E., Mueller, J., Fischer‐Barnicol, B., Achtnichts, L., Findling, O., Lalive, P. H., Bridel, C., Uginet, M., … Kuhle, J. (2025). Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under B‐cell depleting treatment in multiple sclerosis. Annals of Neurology, 97(1), 104–115. https://doi.org/10.1002/ana.27096
Rodríguez-Jorge, F., Fernández-Velasco, J. I., Villarrubia, N., Gracia-Gil, J., Fernández, E., Meca-Lallana, V., Díaz-Pérez, C., Sainz de la Maza, S., Pacheco, E. M., Quiroga, A., Ramió-Torrentà, L., Martínez-Yélamos, S., Bau, L., Monreal, E., López-Real, A., Rodero-Romero, A., Borrega, L., Díaz, S., Eguía, P., … Villar, L. M. (2024). Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis. Frontiers in Immunology, 15, 1480676. https://doi.org/10.3389/fimmu.2024.1480676
Cagol, A., Benkert, P., Schaedelin, S., Ocampo‐Pineda, M., Montobbio, N., Lu, P., Ayci, B., Wenger, A., Shukur, A. A., Kaim, K., Melie‐Garcia, L., Weigel, M., Signori, A., Calabrese, P., Kappos, L., Sormani, M. P., Kuhle, J., & Granziera, C. (2026). Assessing the relative importance of imaging and serum biomarkers in capturing disability, cognitive impairment, and clinical progression in multiple sclerosis. Advanced Science, 13(10), e12946. https://doi.org/10.1002/advs.202512946
Zhu, C., Zhou, Z., Kalincik, T., Roos, I., Buzzard, K., Skibina, O., Alroughani, R., Kuhle, J., Girard, M., Grammond, P., Lechner-Scott, J., Gerlach, O., John, N., McCombe, P., Macdonell, R., van Pesch, V., Laureys, G., Prevost, J., Horakova, D., … Butzkueven, H. (2025). Persistent progression independent of relapse activity in multiple sclerosis. Brain Communications, 7(5), fcaf306. https://doi.org/10.1093/braincomms/fcaf306
Filippi, M., Danesi, R., Derfuss, T., Duddy, M., Gallo, P., Gold, R., Havrdová, E. K., Kornek, B., Saccà, F., Tintoré, M., Weber, J., & Trojano, M. (2022). Early and unrestricted access to high-efficacy disease-modifying therapies: A consensus to optimize benefits for people living with multiple sclerosis. Journal of Neurology, 269(3), 1670–1677. https://doi.org/10.1007/s00415-021-10836-8
Thebault, S., Booth, R. A., Rush, C. A., MacLean, H., & Freedman, M. S. (2021). Serum neurofilament light chain measurement in MS: Hurdles to clinical translation. Frontiers in Neuroscience, 15, 654942. https://doi.org/10.3389/fnins.2021.654942
Ponzio, M., Santoni, L., Molina, M., Tavazzi, E., & Bergamaschi, R. (2025). Economic burden of multiple sclerosis in an italian cohort of patients on disease-modifying therapy: Analysis of disease cost and its components. Journal of Neurology, 272(1), 50. https://doi.org/10.1007/s00415-024-12729-y
Bhan, V., Clift, F., Baharnoori, M., Thomas, K., Patel, B. P., Blanchette, F., Adlard, N., Vudumula, U., Gudala, K., Dutta, N., Grima, D., Mouallif, S., & Farhane, F. (n.d.). Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. Journal of Comparative Effectiveness Research, 12(9), e220175. https://doi.org/10.57264/cer-2022-0175
Suk, K., & Lee, W.-H. (2026). GV1001: Repurposing a telomerase-derived peptide for neurological therapeutics. Expert Opinion on Investigational Drugs, 35(5), 369–381. https://doi.org/10.1080/13543784.2026.2674652
Hou, B., Yin, J., Liu, S., Guo, J., Zhang, B., Zhang, Z., Yang, L., Tan, X., Long, Y., Feng, S., Zhou, J., Wu, Y., Wang, X., Han, S., Wang, Z., & He, X. (2024). Inhibiting the NLRP3 inflammasome with MCC950 alleviates neurological impairment in the brain of EAE mice. Molecular Neurobiology, 61(3), 1318–1330. https://doi.org/10.1007/s12035-023-03618-y
Poon, M. M., Lorrain, K. I., Stebbins, K. J., Edu, G. C., Broadhead, A. R., Lorenzana, A. J., Roppe, J. R., Baccei, J. M., Baccei, C. S., Chen, A. C., Green, A. J., Lorrain, D. S., & Chan, J. R. (2024). Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 121(32), e2407974121. https://doi.org/10.1073/pnas.2407974121
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Natalia Kitala, Justyna Karliczek, Katarzyna Nycz, Julia Knap, Jędrzej Sztajura
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
